Rare FNIP1 mutation acts like a GLP-1 drug, boosting fat burn and lowering disease risk
In a study of over a million people, researchers found a rare loss‑of‑function FNIP1 mutation carried by about 150 individuals (roughly 1 in 7,000) that causes faster energy burning and less fat storage, with carriers exhibiting lower lipids, less liver fat, lower blood sugar, more muscle, and about 60% lower odds of obesity, diabetes and related diseases. Lab work showed silencing FNIP1 in liver cells activates fat‑burning genes, and mice on a fatty diet with FNIP1 pathway inhibition gained less weight and had better insulin sensitivity. The work suggests FNIP1 could be a target for drugs that mimic these effects, but safety concerns remain—especially with two broken copies—and researchers note any therapy would be years away and may require liver‑focused approaches.
